Literature DB >> 1848097

Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP).

H Furuya1, M J Saraiva, M A Gawinowicz, I L Alves, P P Costa, H Sasaki, I Goto, Y Sakaki.   

Abstract

Transthyretin (TTR) is a plasma protein interacting with thyroxine T4 and retinol binding protein (RBP). Several variants of TTR with single amino acid substitutions have been identified as the major components of the amyloid fibrils of familial amyloidotic polyneuropathy (FAP), a fetal, autosomal dominant genetic disease. The elucidation of the molecular nature of the variants distinct from that of the wild-type TTR is crucial for understanding the amyloidogenesis in FAP, but our understanding is very poor mainly because of the unavailability of pure variant TTRs. In the present study, we used an Escherichia coli OmpA secretion vector (Ghrayeb et al., 1984) and achieved an effective production of the variant TTRs related to FAP including Met-30, Ile-33, Ala-60, Tyr-77, Met-111, and Ile-122 types. The variant TTRs produced in this system were efficiently secreted to the culture media. The chemical analysis showed that the secreted TTR (Met-30 type) has the same N-terminus as the native one. IEF analyses also indicated that the secreted product is properly processed as assessed by its pI. Furthermore, the secreted TTR was shown to have biological activities, namely, the thyroxin binding activity and the ability to associate with retinol binding protein, indicating that the secreted TTR polypeptide is properly folded. The present work also demonstrated that the processing/secretion of the recombinant TTR molecules in E. coli was strongly affected by single amino acid substitutions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848097     DOI: 10.1021/bi00223a017

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  26 in total

1.  Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.

Authors:  Mónica Mendes Sousa; Rui Fernandes; Joana Almeida Palha; Ana Taboada; Paulo Vieira; Maria João Saraiva
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity.

Authors:  C Redondo; A M Damas; M J Saraiva
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

3.  Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.

Authors:  Luís Gales; Sandra Macedo-Ribeiro; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva; Ana Margarida Damas
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

4.  Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.

Authors:  G Goldsteins; H Persson; K Andersson; A Olofsson; I Dacklin; A Edvinsson; M J Saraiva; E Lundgren
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  αB-crystallin (HspB5) in familial amyloidotic polyneuropathy.

Authors:  Joana Magalhães; Sofia Duque Santos; Maria João Saraiva
Journal:  Int J Exp Pathol       Date:  2010-08-27       Impact factor: 1.925

6.  Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.

Authors:  Maria Rosário Almeida; Bárbara Macedo; Isabel Cardoso; Isabel Alves; Gregorio Valencia; Gemma Arsequell; Antoni Planas; Maria João Saraiva
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

7.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.

Authors:  M R Almeida; A M Damas; M C Lans; A Brouwer; M J Saraiva
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

8.  Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design.

Authors:  Isabel Cardoso; Maria Rosário Almeida; Nelson Ferreira; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva
Journal:  Biochem J       Date:  2007-11-15       Impact factor: 3.857

9.  Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.

Authors:  Yutaka Takaoka; Mika Ohta; Kazuhisa Miyakawa; Osamu Nakamura; Misao Suzuki; Kiyoshi Takahashi; Ken-Ichi Yamamura; Yoshiyuki Sakaki
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Resveratrol administration increases Transthyretin protein levels ameliorating AD features- importance of transthyretin tetrameric stability.

Authors:  L M Santos; D Rodrigues; M Alemi; S C Silva; C A Ribeiro; I Cardoso
Journal:  Mol Med       Date:  2016-06-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.